Anatara Lifesciences Ltd · ASX:ANR
Anatara Lifesciences — Shareholder Meeting (November 2015)
24 slides from Anatara Lifesciences's shareholder meeting presentation, Nov 11, 2015
Slide 1: Annual General Meeting
For personal use only Annual General Meeting Wednesday 11 November 2015
Slide 2: Disclaimer
Disclaimer For personal use only The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN
Slide 3: Key Financial Details
Key Financial Details For personal use only ASX Code ANR Share Price1 $0.94 Market Cap $46.33 million Ordinary Shares2,3 49,288,246 Raised at IPO (October 2014) $7 million Placement and SPP (July 2015) $9 million Current Cash1 $13.1 million 1. As at 10th November 2015 2. 13,036,095 shares held by di
Slide 4: ANR Chart
4 For personal use only ANR Chart
Slide 5: Oral therapeutics for gastrointestinal disease
Oral therapeutics for gastrointestinal disease For personal use only Detach™ • Natural, non-antibiotic therapeutic that prevents and treats diarrhoea • Meets the need to reduce antibiotics in animal production • Unlike antibiotics, Detach™ will not contribute to antimicrobial resistance
Slide 6: Lead Indication – Pigs
Lead Indication – Pigs Diarrhoea affects hundreds of millions of piglets born each year For personal use only 6
Slide 7: Market Opportunity is clear
Market Opportunity is clear For personal use only • Pork is #1 consumed meat in the world. Global demand for meat is rising • Demand for non-antibiotic treatments continue to rise as authorities restrict use of antibiotics in farm animals • Consumers want their meat to be safe – and antibiotic free
Slide 8: Need to combat anti-microbial resistance
Need to combat anti-microbial resistance For personal use only • Anti-microbial resistance is a worldwide threat to public health • Tens of thousands of people die every year because of antibiotic resistant bacteria – so called “Super Bugs” (USA CDC, WHO) • Antibiotic resistance is driven by antibio
Slide 9: Detach: Poised for swift market entry
Detach™ Poised for swift market entry For personal use only • Launch planned in Australia for 2016 • Has a clear path to market • Proven efficacy (therapeutic claims) • Proven safety - active ingredient is GRAS (generally recognised as safe) • Manufacturing and global supply confirmed • Regulatory r
Slide 10: ANR Achievements
ANR Achievements Positive results from 1st field trial For personal use only Board and Executive Team strengthened IPO closes oversubscribed at 7 million US FDA Fee Waiver granted Positive results from 2nd field trial 2014 2015 ANR Lists on the ASX Successful capital raising $4.4m Successful SPP rai
Slide 11: Upcoming Milestones
Upcoming Milestones For personal use only Third field trial starts 1st Partnering Deal Calf trials 2017-2018 2016-2017 Chicken Trials Animal Safety Trials Detach sales in Asia Submission of dossier to APVMA Human Partner EU and USA Field Trials to start USA Licence application Approval and Registrat
Slide 12: Partnering/Deal Flow Update
Partnering/Deal Flow Update For personal use only • Engaged with Top 12 animal health multi-nationals • Very strong & genuine level of interest • Due diligence on Detach™ is underway • First deal expected by 1st Qtr. 2016 • Australian distribution in place • Opportunity to move direct into Asian mar
Slide 13: Commercialisation strategy
Commercialisation strategy For personal use only Global Market Development • Australia – Home Test market, directly to pork producers (15 companies control 85% of the Australia pig industry) • Overseas - Co-development and commercialisation partners in Europe and US; expansion into Asia • Expansion
Slide 14: Operations Update
For personal use only Operations Update
Slide 15: Manufacturing Update
Manufacturing Update For personal use only Manufacture • Completed GMP manufacture of three commercial scale batches of Detach™ • Stability studies for registration ongoing Current 50 kg scale • Global market capacity assured (≈500,000 doses) Regulatory - Australia • Appointment of Australian Adviso
Slide 16: Regulatory Update - USA
Regulatory Update - USA For personal use only • Appointment of Key Regulatory Advisors • Fee Waiver granted • Positive pre-submission meeting held with the Center for Veterinary Medicine (FDA) to assess Detach registration plans in the USA – Unprecedented amount of interest expressed by the FDA – 19
Slide 17: Regulatory Update - UK
Regulatory Update - UK For personal use only • Appointment of Key Advisors • SME status received (90% reduction in fees) • Positive pre-submission meeting held with the Veterinary Medicines Directorate (UK) to assess Detach registration plans in the EU – Confirm “Claim” and “Dose” – Select method of
Slide 18: Intellectual Property Update
Intellectual Property Update For personal use only • PCT application filed (August 2015) • Second USA patent filed (August 2015) • Solid patent strategy in place for further patents to be filed in major territories • Claims cover the Detach™ formulation, as well as use of the active ingredient and c
Slide 19: Field Trial Update
Field Trial Update For personal use only Previous Trials • 20 positive field trials on commercial farms • Detach™ safe and effective in several thousand piglets Re-registration Trials • Successful trial in Spain (ANR 12-001) • Successful trial in Northern Victoria (ANR 14-001) • Successful trial in
Slide 20: Detach Key Benefits
DetachTM Key Benefits For personal use only • Detach™ is an orally administered non-antibiotic preventative and treatment for scour • Detach™ is safe and effective • Detach™ is broad acting and addresses a range of causes of scour – it’s efficacy does not depend on the cause of scour • A single dose
Slide 21: Detach Mode of action
DetachTM Mode of action DetachTM does not target the pathogen DetachTM acts on the underlying cause of diarrhoea For personal use only 21
Slide 22: Board
Board For personal use only Mel pic Paul G Jay Dr Mel Bridges Paul A. Grujic Dr Jay Hetzel Chairman Director Director Iain Tracie Steve Iain Ross Dr Tracie Ramsdale Stephen Denaro Director Director Company Secretary 22
Slide 23: Management
Management For personal use only Paul Tracey Damian Dr Paul Schober Dr Tracey L. Mynott Damian Wilson Chief Executive Officer Chief Scientific Officer Business Development Kevin David Hayley Hayley Dr Kevin Woodward Dr David Venables Hayley van der Meer Alan Dowling Regulatory Advisor Senior Advisor
Slide 24: Thank you
For personal use only Thank you “With the world’s meat production needs set to rise 100% by 2050, it is important we act now to develop non-antibiotic treatment options.” Dr Mel Bridges, Chairman – Anatara Lifesciences Mel Bridges, Chairman Paul Schober, CEO Tracey Mynott, CSO melbridges@parmacorp.c
Anatara Lifesciences — Shareholder Meeting (November 2015) on 6ix